Clinical trials: Oral Disorder
Breakthrough Bleeding
A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale
This is a 4-arm study to evaluate and compare bleeding patterns between three different doses of DR-1031 oral contraceptive with Seasonale oral contraceptive.
- Trial name
- NCT00394771
- Testing
- DR-1031, Seasonale®, Portia®
- Where
- 50 sites in United States
- Volunteers
- 567 people, healthy volunteers welcome
- Sponsor
- Duramed Research
Dental Caries
Evaluation of Oral Hygiene Products in an In Situ Caries Model
The study will evaluate and compare the potential anti-caries efficacy of a test regimen: placebo (fluoride free) toothpaste (twice daily use) plus fluoride mouthwash (once daily use), in comparison with brushing with a placebo…
- Trial name
- NCT02399163
- Testing
- Fluoride free toothpaste, Fluoride toothpaste, Fluoride mouthwash
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers
This study will be conducted in a single centre, as an open single dose two parallel cohorts design with oral doses of MMV390048 administered in healthy male and female subjects between 18 to 55 years of age.
- Trial name
- NCT02554799
- Testing
- MMV390048 formulation A, MMV390048 formulation B
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Cardiovascular Disease
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Background: Cardiovascular disease (CVD) is a leading cause of death in developed countries. Although statin-type drugs are currently the most effective therapeutic agents for reducing CVD risk.
- Trial name
- NCT01131299
- Testing
- Alpha cyclodextrin
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of…
- Trial name
- NCT00147498
- Testing
- CP-690,550
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 264 people
- Sponsor
- Pfizer
Hypertrophic Cardiomyopathy
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and improving ventricular compliance.
- Trial name
- NCT05135871
- Testing
- Mavacamten
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- LianBio LLC
Lung Cancer
Oral Cell DNA Adducts in Smokers
DNA adducts in the oral mucosa cells of 100 smokers from 3 ethnic groups - Native Hawaiians, Whites, and Japanese Americans with differing risks for lung cancer upon cigarette smoking will be quantified.
- Trial name
- OCDNA (NCT03285893)
- Testing
- oral cell DNA adducts
- Where
- United States
- Volunteers
- 281 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.
- Trial name
- NCT00716092
- Testing
- Sitagliptin, Linagliptin
- Where
- 3 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Background: The new drug BMN 673 (talazoparib) has been shown to fight tumor cells in animals and some people. It is a poly (ADP-ribose) polymerase (PARP) inhibitor.
- Trial name
- NCT02326844
- Testing
- BMN 673 (talazoparib)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Oral Mucositis
Cox-2 Inhibition in Radiation-induced Oral Mucositis
Oral mucositis refers to ulcerative lesions of the oral mucosa that occur due to radiation therapy given for treatment of head and neck cancer.
- Trial name
- NCT00698204
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- UConn Health
Stroke
WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.
- Trial name
- WAVECREST2 (NCT03302494)
- Testing
- Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
- Where
- 25 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- Coherex Medical
HIV Infections
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
This study will aim to evaluate the effect of therapeutic and supratherapeutic oral doses of GSK3640254 on cardiac conduction compared to placebo and a single oral dose of Moxifloxacin in healthy adult participants.
- Trial name
- NCT04563845
- Testing
- GSK3640254, Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Adult Solid Neoplasm, Childhood Solid Neoplasm
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or…
- Conditions
- Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT02116777
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 22 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Bone Loss, Alveolar
Short Dental Implants (5 mm) Versus Long Dental Implants (10 mm)
The purpose of this study is to evaluate the survival rate of 5 mm short implants compared to longer implants (10 mm) placed in sinus-grafted sites.
- Trial name
- NCT04144322
- Testing
- Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition, Zimmer T3 with Discrete Crystalline Deposition Ex Hex Parallel Walled implants
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Toothache
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
To evaluate the analgesic efficacy of a single, oral dose of a naproxen sodium extended-release tablet, compared to placebo in postsurgical dental pain.
- Trial name
- NCT00720057
- Testing
- Naproxen Sodium ER (BAYH6689)
- Where
- 3 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Bayer
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Systemic Sclerosis, Scleroderma
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs…
- Conditions
- Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma
- Trial name
- NCT04837131
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Michael M. Pham
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.